Histogenesis of clear cell adenocarcinoma in the urinary tract: Evidence of urothelial origin

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 1947-1955

  Sung, Ming Tse ^a   Zhang, Shaobo ^b   MacLennan, Gregory T ^c   Lopez Beltran, Antonio ^d   Montironi, Rodolfo ^e   Wang, Mingsheng ^b   Tan, Puay Hoon ^f   Cheng, Liang ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF CÓRDOBA   (Spain)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR CDX2; UROPLAKIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTESTINE METAPLASIA; MALE; PRIORITY JOURNAL; URINARY TRACT CARCINOMA; UROGENITAL TRACT CANCER; X CHROMOSOME; X CHROMOSOME INACTIVATION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM; X CHROMOSOME INACTIVATION;

EID: 42249111524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4147     Document Type: Article

References (45)

1. Konnak JW. Mesonephric carcinoma involving the urethra. J Urol 1973;110:76-8.
2. Chor PJ, Gaum LD, Young RH. Clear cell adenocarcinoma of the urinary bladder: report of a case of probable mullerian origin. Mod Pathol 1993;6:225-8.
3. Drew P, Murphy WM, Civantos F, et al. The histogenesis of clear cell adenocarcinoma of the lower urinary tract: case series and review of the literature. Hum Pathol 1996;27:248-52.
4. Mai KT, Yazdi HM, Perkins DG, et al. Multicentric clear cell adenocarcinoma in the urinary bladder and the urethral diverticulum: evidence of origin of clear cell adenocarcinoma of the female lower urinary tract from Mullerian duct remnants. Histopathology 2000;36:380-2.
5. Kunze E. Histogenesis of nonurothelial carcinomas in the human and rat urinary bladder. Exp Toxicol Pathol 1998;50:341-55.
6. Oliva E, Amin MB, Jimenez R, et al. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol 2002;26:190-7.
7. Hartmann A, Junker K, Dietmaier W, et al. Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol 2006;37:117-20.
8. Suttmann H, Holl-Ulrich K, Peter M, et al. Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder. Urology 2006;67:846.e7-8.
9. Eble JN, Sauter G, Epstein JI, et al. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
10. Sung MT, Jiang Z, Montironi R, et al. α-Methylacyl-CoA racemase P504S/34βE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum Pathol 2007;38:332-41.
11. Sung MT, Jones TD, Beck SD, et al. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol 2006;37:662-7.
12. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004;101:2006-10.
13. Sung MT, Lopez-Beltran A, Eble JN, et al. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol 2006;19:1395-401.
14. Sung MT, Wang M, Maclennan G, et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol 2007;211:420-430.
15. Mashal RD, Lester SC, Sklar J. Clonal analysis by study of X chromosome inactivation in formalin-fixed paraffin-embedded tissue. Cancer Res 1993;53:4676-79.
16. Young RH, Scully RE. Clear cell adenocarcinoma of the bladder and urethra. A report of three cases and review of the literature. Am J Surg Pathol 1985;9:816-26.
17. Torenbeek R, Lagendijk JH, van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998;32:20-7.
18. Gilcrease MZ, Delgado R, Vuitch F, et al. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol 1998;29:1451-6.
19. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-41.
20. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-33.
21. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994;151:545-60.
22. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
23. Okada S, Tsuda H, Takarabe T, et al. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn J Cancer Res 2002;93:798-806.
24. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533-9.
25. Cheng L, Gu J, Eble JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipoma. Am J Surg Pathol 2001;25:1231-6.
26. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004;28:1341-6.
27. Bircan S, Candir O, Kapucuoglu N, et al. CD10 expression in urothelial bladder carcinomas: a pilot study. Urol Int 2006;77:107-13.
28. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smoothmuscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14:465-71.
29. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003;27:178-86.
30. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689-96.
31. Ko S, Chu KM, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol 2005;205:615-22.
32. Osawa H, Kita H, Satoh K, et al. Aberrant expression of CDX2 in the metaplastic epithelium and inflammatory mucosa of the gallbladder. Am J Surg Pathol 2004;28:1253-4.
33. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and α-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005;18:1217-22.
34. Ferdinandusse S, Denis S, L IJ, et al. Subcellular localization and physiological role of α-methylacyl-CoA racemase. J Lipid Res 2000;41:1890-6.
35. Luo J, Zha S, Gage WR, et al. α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
36. Rubin MA, Zhou M, Dhanasekaran SM, et al. α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
37. Jiang Z, Fanger GR, Woda BA, et al. Expression of α-methylacyl-CoA racemase P504s in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003;34:792-6.
38. Skinnider BF, Oliva E, Young RH, et al. Expression of α-methylacyl-CoA racemase P504S in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol 2004;28:701-5.
39. Xiao GQ, Burstein DE, Miller LK, et al. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med 2006;130:805-10.
40. Jiang J, Ulbright TM, Younger C, et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med 2001;125:921-3.
41. Moll R, Wu XR, Lin JH, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 1995;147:1383-97.
42. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000;113:683-7.
43. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27:1-10.
44. Meis JM, Ayala AG, Johnson DE. Adenocarcinoma of the urethra in women. A clinicopathologic study. Cancer 1987;60:1038-52.
45. Oliva E, Young RH. Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. Mod Pathol 1996;9:513-20.